Table 1.
Participant Characteristics
| Entire Cohort (n=467) |
CSF VL Undetectable (n=389) |
CSF VL Detectable (n=78) |
P Value | |
|---|---|---|---|---|
| White, No. (%) | 205 (44) | 182 (46.8) | 23 (29.5) | <.01 |
| Male, No. (%) | 379 (81) | 318 (82) | 61 (78) | NS |
| Mean age (SD), y | 44 (8) | 44 (8) | 42 (7) | .03 |
| Education, mean (SD), y | 12 (2) | 13 (2) | 12 (2) | NS |
| AIDS, No. (%) | 359 (77) | 295 (76) | 64 (82) | NS |
| CD4 count, median (IQR) | 406 (230–587) | 428 (268–612) | 224 (106–434) | <.001 |
| CD4 nadir, median (IQR) | 116 (27–209) | 118 (27–210) | 99 (25–200) | NS |
| Viral load, median (IQR) c/mL | ||||
| Plasma (log10) | 1.7 (1.7–2.6) | 1.7 (1.7–2.1) | 3.9 (2.6–4.7) | <.001 |
| CSF (log10) | 1.7 (1.7–1.7) | All ≤ 1.7 | 2.5 (1.71–3.0) | |
| ARV drugs being taken, median (IQR), No. | 3 (3–4) | 3 (3–4) | 3 (3–3) | NS |
| Receiving current regimen ≥3 mo, No. (%)a | 327 (74) | 282 (78) | 45 (58) | <.001 |
| Type of ARV regimen, No. (%) | .01 | |||
| PI-based | 135 (29) | 108 (28) | 27 (35) | |
| NNRTI-based | 171 (37) | 153 (39) | 18 (23) | |
| 3-Drug regimen | 150 (32) | 120 (31) | 30 (38) | |
| 2-Drug regimen | 10 (2) | 7 (2) | 3 (4) | |
| 1-Drug regimen | 1 (<1) | 1 (<1) | 0 |
Abbreviations: ARV, antiretroviral; CSF, cerebrospinal fluid; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NS, not significant; PI, protease inhibitor; VL, viral load.
a
Data available for n=439.